Product Information

VYVANSE 50 MG CHEWABLE TABLET is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3625 per EA under NDC 59417011901. Its NADAC has been published 341 times since Dec 18, 2019.

The High Outlier badge above means this manufacturer's average price in the LISDEXAMFETAMINE DIMESYLATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

VYVANSE 50 MG CHEWABLE TABLET

LISDEXAMFETAMINE DIMESYLATE
$12.3625per EA
High Outlier
DEA Schedule CII

Strength

50 mg/1

NDC

59417011901

Classification

Brand

Dosage Form

TABLET, CHEWABLE

Route

ORAL

Last Updated

6/17/2026

Active Ingredients

LISDEXAMFETAMINE DIMESYLATE

Approval Type

New Drug (NDA)

FDA Application

NDA208510

On Market Since

1/28/2017

Pharmacological Classes

Central Nervous System Stimulant
Central Nervous System Stimulation

Price Statistics

The NADAC for VYVANSE 50 MG CHEWABLE TABLET has been published 341 times since Dec 18, 2019, and over the history we have for it it has risen 27.7%. The table below summarizes its recorded NADAC range and movement.

Current price$12.3625 per EA
All-time high$12.4384 (Jun 12, 2024)
All-time low$9.6807 (Dec 18, 2019)
52-week high$12.3704
52-week low$12.3200
Median price$11.7800
Average price$11.4810
Largest weekly change+5.0% (Jan 11, 2023)
Weeks tracked341
Tracking sinceDec 18, 2019

Price History

1W

0.0%

1M

+0.1%

3M

+0.2%

6M

+0.3%

1Y

-0.1%

3Y

+4.8%

5Y

+16.6%

All

+27.7%

Generic Alternatives

The matcher finds 3 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 3 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 77% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of VYVANSE 50 MG CHEWABLE TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 50 MG CHEWABLE TABLET, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3625 per EA (NDC 59417011901), effective Jun 24, 2026.

How has the price of VYVANSE 50 MG CHEWABLE TABLET changed over time?

Over the history we have for it, the NADAC for VYVANSE 50 MG CHEWABLE TABLET has risen 27.7%. It has been tracked across 341 weekly CMS publications since Dec 18, 2019.

What are the highest and lowest recorded NADAC prices for VYVANSE 50 MG CHEWABLE TABLET?

Since Dec 18, 2019, the NADAC for VYVANSE 50 MG CHEWABLE TABLET has ranged from a low of $9.6807 (Dec 18, 2019) to a high of $12.4384 (Jun 12, 2024), with a median of $11.7800 per EA.

Are there cheaper alternatives to VYVANSE 50 MG CHEWABLE TABLET?

Yes. 3 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LISDEXAMFETAMINE 50 MG CAPSULE, is $2.8866 per EA — about 77% below VYVANSE 50 MG CHEWABLE TABLET.

Who manufactures VYVANSE 50 MG CHEWABLE TABLET?

VYVANSE 50 MG CHEWABLE TABLET (NDC 59417011901) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.